Ola Melin

Direttore operativo presso CIRCIO HOLDING ASA

Health Technology

Consumer Services

Profilo

Ola Melin is currently the Chief Operating Officer at Circio Holding ASA. Prior to this role, she worked as the Director of Technical Operations at OxThera AB and as the Director of Extended Manufacturing at Swedish Orphan Biovitrum AB.
Ms. Melin completed her undergraduate degree at Mälardalen University.

Posizioni attive di Ola Melin

Società	Posizione	Inizio
CIRCIO HOLDING ASA	Direttore operativo	-

Tutte le posizioni attive di Ola Melin

Precedenti posizioni note di Ola Melin

Società	Posizione	Fine
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Direttore Tecnico/Scientifico/R&S	-
SWEDISH ORPHAN BIOVITRUM AB	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Ola Melin

Formazione di Ola Melin

Mälardalen University

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ola Melin

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
SWEDISH ORPHAN BIOVITRUM AB	Health Technology
CIRCIO HOLDING ASA	Health Technology

Aziende private	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology